These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 11688535

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
    Goldstein BP, Candiani G, Arain TM, Romanò G, Ciciliato I, Berti M, Abbondi M, Scotti R, Mainini M, Ripamonti F.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1580-8. PubMed ID: 7492108
    [Abstract] [Full Text] [Related]

  • 5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT, Tsuji BT.
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF, Moeck G, Draghi DC, Pillar CM, Sahm DF.
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro activity of LY 333328 against anaerobic gram-positive bacteria.
    Sillerström E, Wahlund E, Nord CE.
    J Chemother; 1999 Apr; 11(2):90-2. PubMed ID: 10326737
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC, Hrebickova L.
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R.
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.